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Abstract The acute phase protein haptoglobin is highly ex-
pressed in arteries after sustained £ow changes and involved in
cell migration and arterial restructuring. In the liver, haptoglo-
bin expression is mainly regulated by interleukin-6 (IL-6). In the
artery, shear stress and NO in£uence IL-6 expression. In the
present study, we demonstrate that NO synthesis is involved in
the regulation of arterial haptoglobin expression after sustained
£ow changes. Decreased haptoglobin expression after NO inhi-
bition coincided with decreased IL-6 levels. However, IL-6
knockout mice had normal arterial haptoglobin expression levels
after sustained £ow changes suggesting that other mediators
may provide compensatory mechanisms for the regulation of
arterial haptoglobin expression.
' 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Chronic changes in blood £ow induce structural remodeling
of the arterial wall to normalize shear stress [1]. Structural
remodeling is an important determinant of luminal narrowing
after balloon angioplasty and in de novo atherosclerosis. Pre-
viously, we demonstrated that arterial expression of the acute
phase protein haptoglobin is increased during arterial remod-
eling after sustained £ow changes and plays an important role
in cell migration and arterial restructuring [2]. However, the
regulatory pathways involved in arterial haptoglobin expres-
sion are unknown.
Liver haptoglobin expression is thought to be mediated
through interleukin-6 (IL-6), rather than other in£ammatory
cytokines like glucocorticoids or tumor necrosis factor K
(TNFK). This is supported by point mutations in IL-6 respon-
sive elements in the haptoglobin promoter region, resulting in
lower serum haptoglobin levels [3,4]. Arterial IL-6 expression
has been demonstrated in endothelial and smooth muscle cells
during atherosclerosis [5,6], pointing to a regulatory role in
arterial haptoglobin expression.
IL-6 expression in endothelial cells can be regulated by
shear stress [7] and nitric oxide (NO) [8]. NO is an important
mediator of arterial remodeling as is demonstrated by studies
using either NO synthase (NOS) inhibitors [9] or endothelial
NOS (eNOS) [10] and inducible NOS (iNOS) [11] knockout
mice. NO mediates di¡erent processes that lead to arterial
remodeling which involves the modulation of metalloprotein-
ase (MMP) expression and activity [12] and cell migration
[13]. Previous studies have shown that MMP inhibition can
prevent constrictive remodeling and subsequent luminal nar-
rowing [14^17].
We hypothesized that NO production after arterial £ow
changes regulates arterial expression of haptoglobin, a gela-
tinase inhibitor, through IL-6 expression. In this study, we
show that NO synthesis is involved in the regulation of arte-
rial haptoglobin expression after sustained £ow changes and
suggest that this NO^haptoglobin pathway is an important
cellular mediator between sustained £ow changes and arterial
restructuring.
2. Materials and methods
2.1. Animal models
The investigation conforms with the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of Health
(NIH Publication No. 85-23, revised 1996).
2.1.1. Rabbits. In 14 New Zealand White rabbits, the right carotid
artery was completely ligated which also resulted in £ow increase in
the contralateral left carotid artery. Rabbits received either 1.5 g/l
L-NAME in the drinking water, starting 5 days before intervention
(L-NAME-treated group, n=7) or normal water (control group,
n=7). The carotid arteries of six additional unoperated rabbits were
used to obtain baseline expression levels. The rabbits were anesthe-
tized by intramuscular injection of methadone (0.15 ml) and Ventra-
quil (0.15 ml) followed by intravenous injection of etomidate (1 mg/
kg) and ventilated with N2O:O2 and 0.6% halothane. Animals were
killed 1 day after operation and the carotid, femoral and iliac arteries
were removed. The arteries were snap-frozen in liquid nitrogen and
stored at 380‡C for RNA and protein extraction.
2.1.2. Mice. The IL-6 knockout mice had been backcrossed into
the wild-type B6/129 background for at least 15 generations at the
time of the experiments. Male wild type and IL-6 knockout mice
(n=30) were anesthetized using 0.05 ml/10 g body weight of a cocktail
(1 part Hypnorm, 1 part midazolam, 2 parts distilled water). The right
common carotid artery was ligated as described by Kumar and Lind-
ner [18]. Animals were killed at 0 days (n=5/group) or 3 days (n=10/
group) after operation and the left and right carotid arteries were
removed. The arteries were snap-frozen in liquid nitrogen and stored
at 380‡C for RNA and protein extraction.
2.2. RNA extraction
The frozen tissue samples were ground in liquid nitrogen, using a
pestle and mortar. RNA was extracted using 1 ml Tri-pure1 Isolation
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Reagent (Boehringer Mannheim) according to the manufacturer’s
protocol.
2.3. Northern blotting
Ten Wg of RNA was separated on a 1.2% formaldehyde-agarose gel.
After capillary blotting to Hybond-N membrane (Amersham), the
membrane was baked for 2 h at 80‡C. Probes were prepared using
the random-primed DNA labeling kit (Boehringer Mannheim). Hy-
bridization occurred for 1 h at 65‡C in Easy-Hyb hybridization solu-
tion (Stratagene) followed by 10 min washing in 0.1Ustandard saline
citrate, 0.1% sodium dodecyl sulfate at 65‡C. Bands were visualized
using Biomax MS ¢lms (Kodak).
2.4. Quantitative real-time PCR
Reverse transcription was carried out with 500 ng total RNA using
Superscript II (Life) according to the manufacturer’s protocol. To
con¢rm the identity of the ampli¢ed cDNA products, PCR products
were ligated into the pGEM0-T Easy Vector (Promega) and se-
quenced using the T7 Sequenase version 2.0 DNA sequencing kit
(Amersham).
PCR ampli¢cation was performed using the I-cycler iGTM Real
Time PCR (Bio-Rad). Each reaction contained 14 Wl cDNA, 200
WM dNTP, 1Ureaction bu¡er (Gibco BRL) containing 1:80 0000 Cy-
bergreen (Bio-Rad), 2.5 U Taq DNA polymerase (Gibco BRL) and
1 WM of each primer. Quantities were determined by comparison with
known quantities of the cloned PCR product representing the target
mRNA. Data were corrected for the amount of 18S mRNA that was
used as an internal standard.
The following oligonucleotides were used as primers: rabbit hapto-
globin (forward 5P-GAAGCAGTGGGTGAACAAGG-3P, reverse 5P-
TGACAAGATTGTGGCGGGAG-3P), rabbit interleukin-6 (forward
primer 5P-ACCACGATCCACTTCATCC-3P, reverse primer 5P-TG-
TCCTAACGCTCATCTTC-3P), rabbit 18S (forward primer 5P-TC-
AACACGGGAAACCTCAC-3P, reverse primer 5P-ACAAATCG-
CTCCAGCAAC-3P), mouse haptoglobin (forward 5P-AAAAAC-
CTCTTCCTGAACCAC-3P, reverse 5P-AACGACCTTCTCAATCT-
CCAC-3P), mouse 18S (forward 5P-TCAACACGGGAAACCTCAC-
3P, reverse 5P-ACCAGACAAATCGCTCCAC-3P).
2.5. Statistics
Data are presented as meanSS.E.M. Statistical analysis was per-
formed using the Mann^Whitney U-test. P6 0.05 was considered sta-
tistically signi¢cant.
3. Results
To investigate the role of NO in the regulation of arterial
haptoglobin expression after £ow changes in rabbit carotid
arteries, NO synthesis was inhibited using the non-speci¢c
NOS inhibitor L-NAME. Northern blot analysis showed
that after £ow changes, haptoglobin mRNA levels increased
more in carotid arteries of control rabbits compared to the
carotid arteries of L-NAME-treated rabbits, 1 day after £ow
changes (Fig. 1A).
Quantitative real-time PCR was used to quantify the rela-
tive amounts of haptoglobin mRNA levels in the carotid ar-
teries of unoperated, control and L-NAME-treated rabbits. In
control rabbits, both a £ow increase and a £ow decrease in
the carotid artery resulted in a signi¢cant increase of arterial
haptoglobin mRNA expression compared to baseline values
(30-fold, P=0.005; Fig. 1B). In L-NAME-treated rabbits, a
signi¢cant increase in haptoglobin mRNA levels was observed
compared to baseline values (12-fold, P=0.005). Absolute
haptoglobin mRNA levels, however, were signi¢cantly de-
creased in the carotid arteries of L-NAME-treated rabbits
compared to control rabbits (33%, P=0.04; Fig. 1B). Basal
haptoglobin mRNA expression in unoperated femoral and
iliac arteries was not a¡ected by L-NAME treatment (Fig.
1C).
IL-6 is thought to be the major stimulator of haptoglobin
expression. Therefore, we investigated if IL-6 expression de-
creased after L-NAME treatment. One day after £ow
changes, IL-6 mRNA levels were signi¢cantly increased com-
pared to baseline values in both the left and right carotid
artery of control rabbits (four-fold, P=0.03; Fig. 2A). How-
ever, no increase in IL-6 expression levels was observed in the
carotid arteries of L-NAME-treated rabbits compared to
baseline values. L-NAME treatment had no e¡ect on basal
expression levels of IL-6 mRNA in unoperated femoral and
iliac arteries (Fig. 2B).
To con¢rm the possible role of IL-6 in arterial haptoglobin
expression, haptoglobin expression was measured in IL-6
knockout mice following ligation of the right carotid artery
(Fig. 3). In wild type mice, haptoglobin mRNA levels in-
creased in the left and right carotid artery at 3 days after
ligation of the right carotid artery (two-fold, P=0.05). A sim-
ilar increase in haptoglobin mRNA expression was observed
Fig. 1. Arterial haptoglobin mRNA expression in rabbit carotid ar-
teries after L-NAME treatment, 1 day after sustained £ow changes.
A: Northern blot hybridization showing haptoglobin mRNA expres-
sion in L-NAME-treated and control rabbits, 1 day after £ow
changes. LF=unoperated left femoral artery; LC= left carotid ar-
tery; RC= right carotid artery. B: Haptoglobin mRNA expression
in carotid arteries after sustained £ow changes. C: Haptoglobin
mRNA expression in unoperated femoral and iliac arteries. Hapto-
globin mRNA is presented as the amount of plasmid containing the
haptoglobin PCR product with which it correlates in the dilution se-
ries of this plasmid used in the quantitative real-time PCR. n=7
rabbits/group, *P6 0.05; black bar=baseline values; gray bar=
control rabbits; white bar=L-NAME-treated rabbits.
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in IL-6 knockout mice 3 days after ligation of the carotid
artery (two-fold, P=0.05). Baseline haptoglobin expression
levels did not di¡er between wild type and IL-6 knockout
mice (Fig. 3).
4. Discussion
Haptoglobin expression is increased in arteries after sus-
tained £ow changes and involved in cell migration and arterial
restructuring [2]. The arterial response to normalize wall shear
stress after blood £ow changes depends on a functional vas-
cular endothelium [19] that releases NO as a mediator in the
arterial remodeling process. In the present study, we used the
arterial ligation model to investigate if NO induces arterial
haptoglobin expression after £ow changes.
Inhibition of NO after £ow changes using the non-speci¢c
NOS inhibitor L-NAME partly inhibited arterial haptoglobin
expression. This shows that a NO-dependent pathway is in-
volved in the regulation of arterial haptoglobin expression
after £ow changes. There are at least two isoforms of NOS
expressed in the vascular system after injury or £ow changes
[20^22]. There are, however, di¡erences in function between
those isoforms. NO derived from eNOS inhibits neointimal
formation whereas NO derived from iNOS promotes neointi-
mal formation. Moreover, constrictive remodeling is impaired
in eNOS knockout mice whereas iNOS knockout mice display
more constrictive remodeling compared to wild type mice
[10,11,23]. Unfortunately, the use of L-NAME did not allow
for identi¢cation of the NOS isoform that is involved in the
regulation of arterial haptoglobin expression.
There are no reports demonstrating a direct e¡ect of NO or
shear stress on haptoglobin expression. However, some of the
genes which are regulated by NO appear to depend on the
presence of di¡usible intermediates like cytokines [24]. IL-6
expression is an important regulator of haptoglobin expres-
sion and expressed in both endothelial [7,8] and smooth
muscle cells [5,6] during atherosclerosis. Moreover, IL-6 ex-
pression can be regulated by NO and shear stress [7,8], mak-
ing it a potential candidate to function as an intermediate
between increased NO synthesis and arterial haptoglobin ex-
pression.
To investigate a possible regulatory role for IL-6 in arterial
haptoglobin expression, we measured IL-6 expression levels
after L-NAME treatment. Although the L-NAME-treated
rabbits still responded to £ow changes with increased hapto-
globin mRNA levels, there was a signi¢cant decrease in the
absolute levels of haptoglobin mRNA. This decrease in hap-
toglobin coincided with baseline levels of IL-6, supporting a
regulatory role for IL-6 in arterial haptoglobin expression.
IL-6 knockout mice were used to con¢rm if arterial hapto-
globin expression is indeed regulated through IL-6 after sus-
tained £ow changes. Surprisingly, the IL-6 knockout mice
responded normally to £ow changes with increased haptoglo-
bin mRNA levels, demonstrating that IL-6 is not the only
regulator for the induction of haptoglobin in the arterial
wall. This is in accordance with other studies showing that
IL-6 is not the sole regulator of haptoglobin expression [25].
For instance, the induction of serum haptoglobin in IL-6 and
IL-6/TNF/leukotriene K knockout mice is only slightly re-
duced after stimulation with lipopolysaccharide [26]. Appar-
ently, multiple signals exist which are able to induce hapto-
globin expression and can compensate for de¢ciencies in
regulators like IL-6.
In summary, this study demonstrates that NO synthesis is
involved in arterial expression of haptoglobin after sustained
£ow changes, coinciding with increased IL-6 levels. Since the
increase in haptoglobin expression is normal in IL-6 knockout
Fig. 2. IL-6 mRNA expression in rabbit carotid arteries after
L-NAME treatment, 1 day after sustained £ow changes. IL-6
mRNA is presented as the amount of plasmid containing the IL-6
PCR product with which it correlates in the dilution series of this
plasmid used in the quantitative real-time PCR. A: IL-6 mRNA ex-
pression in carotid arteries after sustained £ow changes. B: IL-6
mRNA expression in unoperated femoral and iliac arteries. n=7
rabbits/group, *P=0.04; LC= left carotid artery; RC= ligated right
carotid artery; black bar=baseline values; gray bar= control rab-
bits; white bar=L-NAME-treated rabbits.
Fig. 3. Haptoglobin mRNA expression in carotid arteries in IL-6
knockout mice after sustained £ow changes. Haptoglobin mRNA is
presented as the amount of plasmid containing the haptoglobin
PCR product with which it correlates in the dilution series of this
plasmid used in the quantitative real-time PCR. n=8^10 arteries/
group, *P=0.05; black bar= carotid arteries, 0 days; gray bar= left
carotid artery 3 days after ligation; white bar= ligated right carotid
arteries, 3 days after ligation.
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mice after £ow changes, we infer that other unidenti¢ed me-
diators may provide compensatory mechanisms for the regu-
lation of arterial haptoglobin expression after £ow changes.
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